Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Ohio State University Comprehensive Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Philogen S.p.A.
Melanoma Institute Australia
University of Michigan Rogel Cancer Center
Vastra Gotaland Region
Melanoma and Skin Cancer Trials Limited
Philogen S.p.A.
University of Birmingham
University of Aleppo
Assistance Publique - Hôpitaux de Paris
The Netherlands Cancer Institute
Nantes University Hospital
Radboud University Medical Center
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
University of Utah
H. Lee Moffitt Cancer Center and Research Institute
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Barbara Ann Karmanos Cancer Institute
Saint John's Cancer Institute
SWOG Cancer Research Network